Private Management Group Inc. Purchases 685,622 Shares of QuidelOrtho Corporation $QDEL

Private Management Group Inc. lifted its position in QuidelOrtho Corporation (NASDAQ:QDEL) by 49.5% during the second quarter, Holdings Channel reports. The institutional investor owned 2,070,391 shares of the company’s stock after buying an additional 685,622 shares during the quarter. Private Management Group Inc.’s holdings in QuidelOrtho were worth $36,263,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of QDEL. Global Retirement Partners LLC lifted its position in QuidelOrtho by 3,691.7% during the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after acquiring an additional 886 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after purchasing an additional 362 shares during the last quarter. GAMMA Investing LLC grew its holdings in QuidelOrtho by 67.7% in the second quarter. GAMMA Investing LLC now owns 2,185 shares of the company’s stock worth $38,000 after purchasing an additional 882 shares during the last quarter. Larson Financial Group LLC increased its position in shares of QuidelOrtho by 322.2% during the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after purchasing an additional 1,015 shares in the last quarter. Finally, Allworth Financial LP acquired a new position in shares of QuidelOrtho during the second quarter worth $56,000. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Stock Performance

Shares of QDEL stock opened at $14.74 on Friday. The business has a fifty day moving average of $15.93 and a 200 day moving average of $16.04. QuidelOrtho Corporation has a 1 year low of $9.92 and a 1 year high of $35.58. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -0.96 and a beta of 0.68.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%.The business had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. During the same period in the prior year, the company earned $0.12 earnings per share. The company’s revenue was up 2.8% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. As a group, research analysts expect that QuidelOrtho Corporation will post 0.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on QDEL shares. Zacks Research lowered QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 12th. UBS Group restated a “neutral” rating and set a $12.00 target price on shares of QuidelOrtho in a research note on Thursday, May 7th. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. Finally, Citigroup boosted their price target on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Three analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.